Benign neonatal seizures
Benign Neonatal Seizures (BNS), also known as Benign Familial Neonatal Seizures (BFNS) when there is a family history, are a type of seizures occurring in newborn infants. These seizures are considered benign because they have a limited duration, typically occurring between the second and eighth day of life, and infants usually outgrow them without developing long-term neurological deficits or epilepsy.
Etiology and Pathophysiology[edit]
The exact cause of BNS is not fully understood, but it is believed to involve genetic factors. Mutations in the genes KCNQ2 and KCNQ3, which encode for potassium channel subunits, have been identified in many cases of BFNS. These channels are crucial for the regulation of neuronal excitability, and mutations can lead to increased neuronal firing, resulting in seizures.
Clinical Presentation[edit]
Infants with BNS experience seizures that are often characterized by apnea (pauses in breathing), tonic (stiffening) or clonic (jerking) movements of the limbs, and ocular movements such as blinking or staring. These seizures are generally brief but can occur multiple times a day while the condition persists.
Diagnosis[edit]
Diagnosis of BNS is based on the clinical presentation and the exclusion of other causes of neonatal seizures. Electroencephalogram (EEG) findings during this period may show characteristic patterns that support the diagnosis. Genetic testing can identify mutations in KCNQ2 or KCNQ3, confirming a diagnosis of BFNS.
Treatment[edit]
Treatment of BNS may not always be necessary, as the condition typically resolves on its own within weeks to months. However, in cases where seizures are frequent or severe, antiepileptic drugs (AEDs) may be used temporarily to control seizures. It is important to monitor infants for potential side effects of these medications.
Prognosis[edit]
The prognosis for infants with BNS is generally excellent. Most infants outgrow the seizures without any developmental delays or neurological issues. However, a small percentage may develop epilepsy later in life, necessitating ongoing monitoring.
See Also[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian